T. Rowe Price Investment Management’s Travere Therapeutics TVTX Stock Holding History

T. Rowe Price Investment Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$15.5M	Buy	+520,604	New	+$15.6M	0.01%	499

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Investment Management's TVTX Position: Q1 2026 in Review

T. Rowe Price Investment Management opened a new position in Travere Therapeutics (TVTX) in Q1 2026: 520,604 shares worth $15.5M. The stake represents 0.01% of the portfolio and ranks #499 among its holdings.

260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

T. Rowe Price Investment Management held 520,604 shares of Travere Therapeutics worth $15.5M as of Q1 2026.
Travere Therapeutics was a new T. Rowe Price Investment Management position in Q1 2026.
Travere Therapeutics made up 0.01% of T. Rowe Price Investment Management's portfolio in Q1 2026, its #499 holding.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.